Crinetics Pharmaceuticals (NASDAQ:CRNX) Lowered to Sell at Zacks Investment Research

Zacks Investment Research cut shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) from a hold rating to a sell rating in a report released on Friday, Zacks.com reports.

According to Zacks, “Crinetics Pharmaceuticals Inc is a clinical stage pharmaceutical company. It focuses on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s product pipeline consists of CRN00808 for the treatment of Acromegaly, CRN02481 for the treatment of Hyperinsulinemias and CRN01941 for the treatment of Neuroendocrine Tumors which are in clinical stage. Crinetics Pharmaceuticals Inc is based in San Diego, United States. “

CRNX stock opened at $18.73 on Friday. The stock has a 50-day moving average price of $22.20 and a two-hundred day moving average price of $23.99. The company has a current ratio of 19.07, a quick ratio of 18.04 and a debt-to-equity ratio of 0.04. Crinetics Pharmaceuticals has a 1 year low of $17.32 and a 1 year high of $42.00.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last released its earnings results on Tuesday, August 13th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.05). Crinetics Pharmaceuticals had a negative return on equity of 24.12% and a negative net margin of 1,303.31%. As a group, equities research analysts forecast that Crinetics Pharmaceuticals will post -1.92 earnings per share for the current fiscal year.

In other news, insider Ventures Iv L.P. 5Am sold 250,000 shares of the firm’s stock in a transaction dated Friday, June 21st. The stock was sold at an average price of $22.20, for a total value of $5,550,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 7.40% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in CRNX. Price T Rowe Associates Inc. MD lifted its holdings in shares of Crinetics Pharmaceuticals by 0.4% during the second quarter. Price T Rowe Associates Inc. MD now owns 487,916 shares of the company’s stock worth $12,198,000 after purchasing an additional 1,786 shares during the period. Victory Capital Management Inc. lifted its holdings in Crinetics Pharmaceuticals by 30.5% in the second quarter. Victory Capital Management Inc. now owns 69,670 shares of the company’s stock valued at $1,742,000 after buying an additional 16,300 shares during the period. Citadel Advisors LLC acquired a new position in Crinetics Pharmaceuticals in the second quarter valued at $295,000. Marshall Wace North America L.P. lifted its holdings in Crinetics Pharmaceuticals by 3,768.4% in the second quarter. Marshall Wace North America L.P. now owns 73,925 shares of the company’s stock valued at $1,848,000 after buying an additional 72,014 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in Crinetics Pharmaceuticals by 11.6% in the second quarter. Vanguard Group Inc. now owns 504,539 shares of the company’s stock valued at $12,614,000 after buying an additional 52,327 shares during the period. Institutional investors own 73.70% of the company’s stock.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly.

Read More: New Google Finance Tool and Screening Stocks

Get a free copy of the Zacks research report on Crinetics Pharmaceuticals (CRNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.